A Phase II Trial of BIBW 2992 as a Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type EGFR
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary endpoint is the objective tumour response rate (complete response, partial response) as determined by Response Evaluation Criteria in Solid Tumours version 1.1.
Boehringer Ingelheim Pharmaceuticals
Korea, Republic of: Korea Food and Drug Administration